Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO)

Agnes Dumas, PhD1,2; Ines Vaz Luis, MD, PhD1,4; Thomas Bovagnet, MSc1; Mayssam El Mouhebb, MSc3,4; Antonio Di Meglio, MD4; Sandrine Pinto, MSc4; Cecile Charles, PhD6,7; Sarah Dauchy, MD; Suzette Delaloge, MD, PhD7; Patrick Arveux, MD, PhD8,9; Charles Coutant, MD, PhD10; Paul Cottu, MD, PhD11; Anne Lesur, MD11; Florence Lerebours, MD, PhD12; Olivier Tredan, MD, PhD13; Laurence Vanlemmens, MD14; Christelle Levy, MD15; Jerome Lemonnier, PhD16; Christelle Mesleard, MSc16; Fabrice Andre, MD, PhD1,4; and Gwenn Menvielle, PhD1

PURPOSE Adverse effects of breast cancer treatment can negatively affect survivors’ work ability. Previous reports lacked detailed clinical data or health-related patient-reported outcomes (PROs) and did not prospectively assess the combined impact of treatment and related sequelae on employment.

METHODS We used a French prospective clinical cohort of patients with stage I-III breast cancer including 1,874 women who were working and ≥ 5 years younger than legal retirement age (< 57 years) at breast cancer diagnosis. Our outcome was nonreturn to work (non-RTW) 2 years after diagnosis. Independent variables included treatment characteristics as well as toxicities (Common Toxicity Criteria Adverse Events [CTCAE] v4) and PROs (European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaires, Breast cancer module [QLQ-BR23] and Fatigue module [QLQ-FA12], Hospital Anxiety and Depression Scale) collected 1 year after diagnosis. Logistic regression models assessed correlates of non-RTW, adjusting for age, stage, comorbidities, and socioeconomic covariates.

RESULTS Two years after diagnosis, 21% of patients had not returned to work. Odds of non-RTW were significantly increased among patients treated with combinations of chemotherapy and trastuzumab (odds ratio [OR] chemotherapy-hormonotherapy, 2.01; 95% CI, 1.18 to 3.44; for chemotherapy-trastuzumab-hormonotherapy, 1.62; 95% CI, 1.10 to 2.41). Other significant associations with non-RTW included grade ≥ 3 CTCAE toxicities (OR v no, 1.59; 95% CI, 1.15 to 2.18), arm morbidity (OR v no, 1.59; 95% CI, 1.19 to 2.13), anxiety (OR v no, 1.47; 95% CI, 1.02 to 2.11), and depression (OR v no, 2.29; 95% CI, 1.34 to 3.91).

CONCLUSION Receipt of systemic therapy combinations including trastuzumab was associated with increased odds of non-RTW. Likelihood of unemployment was also higher among patients who reported severe physical and psychological symptoms. This comprehensive study identifies potentially vulnerable patients and warrants supportive interventional strategies to facilitate their RTW.

J Clin Oncol 38:734-743. © 2019 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

INTRODUCTION

More than 85% of patients with breast cancer (BC) live > 5 years after diagnosis in Western countries,1 with a current prevalence reaching > 3 million 5-year survivors in North America and Europe.2 A meta-analysis of 36 North American and European studies suggested that BC survivors were at higher risk of unemployment compared with individuals without a history of cancer.3 One-third of patients with BC are < 55 years old at time of diagnosis,4 with several years within the workforce ahead before retirement, in an era where the legal retirement age is globally increasing.5 Employment issues among BC survivors are therefore a major challenge.

Return to work (RTW) after BC is a complex process that is strongly influenced by medical factors such as treatment and its related adverse events.5-8 Previous studies suggested that work ability could be impaired by chemotherapy,9-12 mastectomy,10,11,13 or axillary node dissection.12,14 In addition, a late onset of adverse effects of BC treatment is possible for a substantial proportion of patients, and many of them experience fatigue, cognitive impairment, psychological distress, and arm dysfunction for a long time after treatment completion.15-18 All these effects can affect employment. Indeed, studies suggested associations of work ability with BC treatment–related adverse events such as shoulder impairment19 and fatigue.20,21 In addition, psychological distress after cancer experience was also shown to adversely affect job reintegration.20,21 Nevertheless, most of the existent evidence comes from cross-sectional studies based on small samples or from retrospective registries or administrative data.
with limited information on treatment. Furthermore, most studies do not evaluate different types of toxicities simultaneously and do not use validated patient-reported outcome (PRO) measures to assess physical and psychological domains. In addition, the therapy landscape for patients with early BC has changed over time, particularly during the last decade. The majority of patients now receive multimodality therapy, including new chemotherapy and endocrine therapy agents and targeted therapies such as trastuzumab. Therefore, a clear and comprehensive assessment of the burden of contemporary BC treatment and its related toxicities on employment is lacking. Understanding the independent impact of BC treatment and its adverse effects on employment is urgently needed to better inform patients, health care providers, employers, and policy makers. The aim of this study was to identify treatment-related correlates of RTW 2 years after diagnosis, using data of a large multicenter cohort of patients with BC, including detailed information on treatment and women’s health status before and after treatment.

METHODS

Data Source

We used data of a prospective clinical cohort of patients diagnosed with stage I-III primary BC and no prior history of cancer other than basal cell skin cancer or in situ cervical carcinoma within the past 5 years (CANTO [Cancer Toxicities]; NCT01993498). Inflammatory BC was excluded. The cohort aimed to assess treatment-related toxicities and their psychosocial impact. Data were collected in 26 French cancer care centers. Treatment and tumor classification were extracted from medical files. Patients’ medical history, prediagnosis comorbidities, and a set of physical treatment-related toxicities were collected during face-to-face health examinations by trained clinical research nurses. PROs were collected by means of validated self-reported paper questionnaires assessing physical and psychological outcomes. Socioeconomic data were gathered through an ad hoc self-reported paper questionnaire gathering items from diverse French population-based surveys. These data were collected prospectively at 3 time points: at diagnosis (baseline); at the first post-treatment visit (T1), 3 to 6 months after the end of primary treatment; and at the second post-treatment visit (T2), which occurred on average 2 years after diagnosis (median, 23 months, interquartile range, 21-25 months; Fig 1). End of primary treatment was defined as the end of primary surgery, chemotherapy, or radiotherapy, whichever came last. Anti–human epidermal growth factor receptor (HER2) therapy and hormonal therapy could be ongoing, if indicated. The study was approved by the French regulatory authorities. All patients enrolled in the study were age ≥ 18 years and provided written informed consent.

Study Cohort

The study included the data of 5,801 patients enrolled in the CANTO cohort between March 21, 2012 and January 7, 2015 (first data lock). We restricted our analysis to women age < 57 years old at time of diagnosis (N = 2,883) for women to be at least 5 years away from the French legal retirement age (62 years old) at baseline. Women with no information on work situation at baseline (n = 124), not employed at baseline (n = 401), and not treated with curative intent (patients with no surgery, n = 2) were excluded, as well as patients with evidence of local or distant recurrence or patients who died before the end of the study (n = 72). Of the 2,284 eligible patients, 124 were lost to clinical follow-up, and 286 did not report information on RTW at T2 (n = 410, 18% of eligible patients). Response rate to RTW assessment questions was associated with age, receipt of hormone therapy, and occupational class but did not differ in terms of stage, number of prediagnosis comorbidities, type of surgery or axillary dissection, or receipt of radiotherapy or chemotherapy (Appendix Table A1, online only). The final study sample included 1,874 respondents (Fig 2).

Variables

Our outcome of interest was non-RTW (binary variable grouping part-time and full-time workers). Information on RTW was collected at T2.

Socioeconomic covariates measured at diagnosis included age (< 40, 40-49, ≥ 50 years), having a partner (yes/no), and number of economically dependent children living in the household (0, 1, > 1). As a proxy of socioeconomic status, we used income of the household (< 2,000€, 2,000-4,000€, > 4,000€) and women’s occupational class according to the 6-category version of the French classification, which is roughly equivalent to the US classification: professionals and managers, technicians and associate professionals, clerks, manual workers, farmers, and self-employed. Because of small numbers, farmers were grouped with self-employed. Part-time and full-time employment before diagnosis were distinguished. Work-life imbalance (whether the woman gave priority to professional or personal life) at diagnosis was also assessed.

Clinical variables included stage (based on American Joint Committee on Cancer 7th edition) and prediagnosis comorbid medical conditions. The latter were evaluated using the Charlson comorbidity index and a binary variable assessing the presence of ≥ 3 additional comorbid medical conditions not captured by the Charlson index but that can have a substantial burden on a woman’s life and affect RTW (among the following medical areas: neurologic, cardiovascular, respiratory, GI, renal, hepatobiliary, endocrine, musculoskeletal, urogenital, hematologic, dermatological, psychiatric).
Treatment variables included receipt of radiotherapy (yes/no), surgery, and systemic treatments. Types of surgery (conservative, mastectomy, axillary node dissection, sentinel node dissection) and types of systemic treatment (chemotherapy, hormone therapy [HT], trastuzumab) were combined as described in Table 1, to account for different therapeutic strategies.

Toxicities and PROs were collected at baseline and at T1. A set of physical toxicities was collected by a clinical research nurse during a face-to-face examination using the Common Toxicity Criteria Adverse Events Scale (CTCAE), version 4,32 and coded as severe when any grade $\geq 3$ toxicity was reported. The number of severe CTCAE toxicities (reported in the following areas: cardiovascular, gynecologic, rheumatological, GI, dermatological, pulmonary, neurologic) was computed and then dichotomized (0, $\geq 1$). Additional physical toxicities were assessed using 3 clinically relevant symptom subscales of the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire, breast cancer module (QLQ-BR23)33,34 (namely: systemic therapy side effects, arm and breast morbidity). These 3 subscales were categorized as severe (yes/no) when a patient scored $\geq 40$ on the respective scale.35,36 Severe physical, emotional, and cognitive fatigue were defined using the EORTC quality of life questionnaire, fatigue module (QLQ-FA12) (score $\geq 50$ on the respective scale).37 Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS).38 Both subscales were categorized into 3 categories (noncase [0-7], doubtful [8-10], case [11-21]). All these variables had $\leq 5\%$ missing values except the Charlson comorbidity index, which had 7% missing values (Appendix Table A2, online only).

**Statistical Analyses**

Binary logistic regression analyses were performed to identify correlates of non-RTW. We first adjusted for treatment variables as well as clinical and socioeconomic covariates collected at diagnosis (model 1) and then additionally adjusted for CTCAE toxicities and PROs collected...
### TABLE 1. Factors Associated With Non-RTW at the Second Post-Treatment Visit 2 Years After Diagnosis: Multivariable Logistic Regressions

| Factor                               | %         | OR      | 95% CI      | OR        | 95% CI     |
|--------------------------------------|-----------|---------|-------------|-----------|------------|
| **Socioeconomic covariates at diagnosis** |           |         |             |           |            |
| Age, years                           |           |         |             |           |            |
| 18-39                                | 13.2      | 1.00    |             | 1         |            |
| 40-49                                | 46.2      | 1.03    | 0.71 to 1.51| 1.01      | 0.68 to 1.50|
| 50-56                                | 40.6      | 1.60    | 1.08 to 2.39| 1.61      | 1.06 to 2.45|
| Having a partner                      |           |         |             |           |            |
| No                                   | 15.9      | 1.00    |             | 1         |            |
| Yes                                  | 84.1      | 1.15    | 0.80 to 1.67| 1.17      | 0.79 to 1.74|
| No. of children                      |           |         |             |           |            |
| 0                                    | 28.9      | 1.00    |             | 1         |            |
| 1                                    | 26.6      | 0.94    | 0.68 to 1.31| 0.88      | 0.63 to 1.24|
| > 1                                  | 44.5      | 0.91    | 0.66 to 1.24| 0.88      | 0.63 to 1.22|
| Occupational class                   |           |         |             |           |            |
| Professionals and managers           | 24.6      | 1.00    |             | 1.00      |            |
| Technicians and associate professionals | 24.0    | 1.00    | 0.68 to 1.47| 0.95      | 0.64 to 1.42|
| Clerks                               | 39.4      | 1.49    | 1.04 to 2.13| 1.42      | 0.97 to 2.07|
| Self-employed (farmers, craftsmen, and shopkeepers) | 5.3   | 1.14    | 0.63 to 2.08| 1.09      | 0.58 to 2.05|
| Manual workers                       | 6.7       | 2.34    | 1.42 to 3.87| 2.17      | 1.28 to 3.69|
| Income of the household              |           |         |             |           |            |
| > 4,000€ per month                   | 32.9      | 1.00    |             | 1.00      |            |
| 2,000-4,000€ per month               | 48.7      | 1.35    | 0.99 to 1.85| 1.26      | 0.90 to 1.75|
| < 2,000€ per month                   | 18.4      | 1.94    | 1.27 to 2.96| 1.65      | 1.06 to 2.59|
| Working hours                        |           |         |             |           |            |
| Full-time employment                 | 75.3      | 1.00    |             | 1.00      |            |
| Part-time employment                 | 24.7      | 1.50    | 1.12 to 2.00| 1.51      | 1.12 to 2.04|
| Work-life imbalance                  |           |         |             |           |            |
| Equal importance to personal and professional life | 47.4   | 1.00    |             | 1.00      |            |
| Personal life is more important      | 39.8      | 1.28    | 0.99 to 1.65| 1.29      | 0.98 to 1.68|
| Professional life is more important  | 9.9       | 1.14    | 0.75 to 1.73| 1.06      | 0.68 to 1.65|
| **Clinical covariates**              |           |         |             |           |            |
| Stage                                |           |         |             |           |            |
| Stage I                              | 44.8      | 1.00    |             | 1.00      |            |
| Stage II                             | 44.0      | 1.28    | 0.94 to 1.76| 1.41      | 1.01 to 1.97|
| Stage III                            | 11.3      | 1.86    | 1.17 to 2.94| 1.99      | 1.22 to 3.23|
| Charlson comorbidity index           |           |         |             |           |            |
| 0                                    | 85.9      | 1.00    |             | 1.00      |            |
| ≥ 1                                  | 14.1      | 1.54    | 1.12 to 2.13| 1.52      | 1.08 to 2.14|
| Additional comorbid conditions       |           |         |             |           |            |
| < 3                                  | 79.4      | 1.00    |             | 1.00      |            |
| ≥ 3                                  | 20.6      | 1.64    | 1.24 to 2.16| 1.39      | 1.03 to 1.87|

(continued on following page)
| Factor                                      | %    | OR   | 95% CI          | OR   | 95% CI          |
|--------------------------------------------|------|------|-----------------|------|-----------------|
| **Treatment**                              |      |      |                 |      |                 |
| Radiotherapy                               |      |      |                 |      |                 |
| No                                         | 8.4  | 1.00 | —               | 1.00 | —               |
| Yes                                        | 91.6 | 0.79 | 0.49 to 1.26    | 0.77 | 0.47 to 1.26    |
| Combinations of local treatments           |      |      |                 |      |                 |
| Conservative surgery + sentinel node dissection | 47.7 | 1.00 | —               | 1.00 | —               |
| Conservative surgery + axillary dissection | 22.2 | 1.13 | 0.78 to 1.63    | 1.06 | 0.72 to 1.56    |
| Mastectomy + sentinel node dissection      | 6.3  | 1.15 | 0.65 to 2.05    | 1.16 | 0.64 to 2.13    |
| Mastectomy + axillary dissection           | 23.8 | 1.72 | 1.19 to 2.48    | 1.65 | 1.12 to 2.44    |
| Combinations of systemic treatments        |      |      |                 |      |                 |
| Chemotherapy + hormone therapy             | 41.2 | 1.00 | —               | 1.00 | —               |
| Hormone therapy alone                      | 30.9 | 0.96 | 0.68 to 1.36    | 1.03 | 0.71 to 1.49    |
| Chemotherapy alone                         | 9.3  | 1.58 | 1.05 to 2.37    | 1.49 | 0.96 to 2.29    |
| Chemotherapy + trastuzumab                 | 4.7  | 2.15 | 1.29 to 3.57    | 2.01 | 1.18 to 3.44    |
| Chemotherapy + trastuzumab + hormone therapy | 10.4 | 1.66 | 1.14 to 2.42    | 1.62 | 1.10 to 2.41    |
| None                                       | 3.5  | 1.32 | 0.66 to 2.65    | 1.42 | 0.67 to 2.97    |
| Toxicities and PROs                       |      |      |                 |      |                 |
| ≥ 1 CTCAE severe physical toxicity        |      |      |                 |      |                 |
| No                                         | 84.5 | —    | 1.00            | —    | 1.59 to 2.18    |
| At least one                               | 15.5 | —    | —               | 1.00 | —               |
| Severe breast morbidity                    |      |      |                 |      |                 |
| No                                         | 75.3 | —    | 1.00            | —    | 0.70 to 1.33    |
| Yes                                        | 24.7 | —    | 0.97            | 1.59 | 1.19 to 2.13    |
| Severe arm morbidity                       |      |      |                 |      |                 |
| No                                         | 73.0 | —    | 1.00            | —    | 1.59            |
| Yes                                        | 27.0 | —    | 1.19 to 2.13    | —    | —               |
| Severe systemic therapy adverse effects    |      |      |                 |      |                 |
| No                                         | 90.9 | —    | 1.00            | —    | 0.95 to 2.14    |
| Yes                                        | 9.1  | —    | 1.43            | 1.00 | 0.94 to 1.83    |
| Severe physical fatigue                    |      |      |                 |      |                 |
| No                                         | 77.2 | —    | 1.00            | —    | 0.94 to 1.83    |
| Yes                                        | 22.8 | —    | 1.31            | —    | 0.94 to 1.83    |
| Severe cognitive fatigue                   |      |      |                 |      |                 |
| No                                         | 84.3 | —    | 1.00            | —    | 0.70 to 1.49    |
| Yes                                        | 15.7 | —    | 1.02            | 1.00 | 0.70 to 1.49    |
| Severe emotional fatigue                   |      |      |                 |      |                 |
| No                                         | 82.2 | —    | 1.00            | —    | 1.00 to 2.13    |
| Yes                                        | 17.8 | —    | 1.46            | 1.00 | 1.00 to 2.13    |
| Anxiety                                    |      |      |                 |      |                 |
| Noncase                                    | 53.3 | —    | 1.00            | —    | —               |
| Doubtful case                              | 26.3 | —    | 1.71            | 1.26 | 1.26 to 2.32    |
| Case                                       | 20.4 | —    | 1.47            | 1.02 | 2.11            |

(continued on following page)
at T1 (model 2). We assessed pairwise correlation between the symptom-related covariates using $X^2$ test and Cramer’s $V$ and tested interactions between correlated variables. Multiple imputations were performed with the fully conditional specification method. We ran sensitivity analyses using QLQ-FA12 subscale scores as continuous variables in the absence of a validated threshold to dichotomize the continuum of scores. We also analyzed the impact of change in severe toxicities between baseline (diagnosis) and T1 for EORTC and HADS subscales.

Odds ratio (ORs) and 95% CIs were estimated. All tests were 2-sided at the 0.05 significance level. The R statistical package (version 3.2.3; R foundation, Vienna Austria) was used.

RESULTS

Cohort Characteristics

The mean age at diagnosis was 47 years. At diagnosis, 24.6% were professionals or managers and 39.4% were clerks (Table 1). A total of 30.0% of women reported comorbidities, measured by the Charlson or the additional comorbidity index. Overall, 30.1% of patients underwent mastectomy; 65.6%, 82.5%, and 15.1% of patients received chemotherapy, HT, and trastuzumab, respectively. The most prevalent combinations of local and systemic treatments were conservative surgery and sentinel node dissection (47.7%) and chemotherapy combined with HT (41.2%).

At the first post-treatment visit (T1), 15.5% of patients reported at least one severe physical CTCAE toxicity. Severe physical, cognitive, and emotional fatigue were reported by 22.8% 15.7%, and 17.8% of patients, respectively. In addition, 20.4% were anxious and 5.5% were depressed.

Two years after diagnosis (T2), 399 (21.3%) patients had not returned to work. Among them, 73.9% were on sick leave, 8.5% were unemployed and seeking work, 5.5% received disability benefit, 6.5% were retired, and 5.6% were in another situation. Among women who worked full time at diagnosis, 23.6% had become part-time employees.

Correlates of Non-RTW

In univariate analyses (Appendix Table A2), patients who had received combinations of treatment with trastuzumab, those who had undergone mastectomy and axillary node dissection, and those who reported severe physical or psychological symptoms were less likely to be working ($P < .001$). In the first regression model focused on treatment characteristics (model 1, Table 1), odds of non-RTW were significantly increased for patients who were <50 years, those who had undergone mastectomy and axillary node dissection, and those who had received combinations of chemotherapy and trastuzumab. Odds of non-RTW were also significantly elevated among women with stage III BC, who reported prediagnosis comorbidities, worked part time at diagnosis, and had lower occupational classes or income (Table 1).

In a separate model that included CTCAE toxicities and PROs collected at T1 (model 2, Table 1), the same associations emerged as compared with model 1, although ORs were reduced among patients with ≥3 additional comorbid conditions and a low occupational class or income. By contrast, the ORs remained stable among patients who had undergone mastectomy and axillary node dissection or patients who were treated with combinations of chemotherapy and trastuzumab. Odds of non-RTW were also significantly elevated among women with stage III BC, who reported prediagnosis comorbidities, worked part time at diagnosis, and had lower occupational classes or income (Table 1).

**TABLE 1.** Factors Associated With Non-RTW at the Second Post-Treatment Visit 2 Years After Diagnosis: Multivariable Logistic Regressions (continued)

| Factor               | Model 1 |          | Model 2 |          |
|----------------------|---------|----------|---------|----------|
| Depression           |         |          |         |          |
| Noncase              | 83.4    | 1.00     |         |          |
| Doubtful case        | 11.1    | 2.29 1.34 to 3.91 | 2.29 1.34 to 3.91 |
| Case                 | 5.5     | 2.29 1.34 to 3.91 | 2.29 1.34 to 3.91 |

NOTE. France, CANTO cohort, 2018; imputed data set. Model 1: ORs are adjusted for socioeconomic covariates, clinical covariates, and treatment. Model 2: ORs are adjusted for all the variables listed in the table.

Abbreviations: CTCAE, Common Toxicity Criteria Adverse Events; $€$, Euros; RTW, return to work; PROs, patient-reported outcomes; OR, odds ratio.

aVariables collected at diagnosis.

bVariables collected at the first post-treatment visit (3-6 months after end of primary treatment).

$^c$CTCAE grade ≥ 3 cardiovascular, gynecologic, rheumatological, GI, dermatological, pulmonary, or neurologic toxicity.
consistent results (data not shown). Models including the type of chemotherapy regimen (anthracycline-taxane based vs other) yielded identical results, and no effect of the chemotherapy regimen on RTW was observed (Appendix Table A3, online only).

DISCUSSION

More than 70% of working-age women are in the labor force in Western countries. Employment after diagnosis and treatment of BC is therefore a major public health challenge.

Our study clarified the independent effect of BC treatment and its impact on employment. BC treatment is now standardized by national and international guidelines. We studied the effect of standard combinations of treatments that reflect the current different therapeutic strategies used in the treatment of nonmetastatic BC. Among local treatments, we found that only the most aggressive strategies (combination of mastectomy and node dissection) had a negative long-term impact on employment. The fact that we looked at these strategies together may explain the inconsistency of the effects previously found in the literature for mastectomy alone or axillary dissection alone.

Regarding systemic treatments, chemotherapy alone was associated with non-RTW in model 1, but not in model 2, when accounting for treatment toxicities. Previous studies on RTW after BC usually included treatment or toxicities, but a few included both (notably fatigue). Over the 4 studies including both fatigue and treatment in multivariable models, most of them did not find that chemotherapy was significantly associated with RTW in patients with BC. Our results suggest an independent effect of trastuzumab on RTW, with significantly increased odds of non-RTW for all combinations that include trastuzumab and chemotherapy (with or without HT), although, on average, patients had stopped trastuzumab 10 months before RTW was assessed (only 1 woman was still treated at T2). Combination of trastuzumab and chemotherapy is the standard of care for patients with biologically aggressive HER2-positive early BC. To our knowledge, only 2 studies on RTW after BC included trastuzumab, with no suggestion of impact of this treatment on employment, but they were based on limited samples. Clinical studies report that trastuzumab is well tolerated by patients, with very few grade 3 toxicities, but potential persistent fatigue. It is possible that patients who receive trastuzumab for HER2-positive BC have subtle clinical late effects, but they may also be more likely to perceive themselves as sick for a longer time, being overwhelmed with fear of relapse and accumulation of treatments.

Part of the influence of treatment on RTW is due to treatment adverse effects. Although health status at diagnosis is a confounding factor in this association, many studies fail to account for prediagnosis comorbidities. Our results underline the importance of these comorbidities, which were strongly associated with RTW and were reported by 30% of the patients, even in our cohort of relatively young patients. Therefore, our results have the ability to suggest the importance of both physical and psychological symptoms at first post-treatment visit on RTW after careful control for prediagnosis comorbidities.

We investigated multiple physical and psychological symptoms. Our study, consistent with prior research, suggested that physical treatment adverse effects such as arm morbidity impact RTW through reduced work capacity. We also investigated the role of fatigue, which has been shown to have an effect on RTW of BC survivors. In previous studies, fatigue was measured through questionnaires assessing global fatigue, combining the different aspects of fatigue (eg, physical, emotional). This is the first report, to our knowledge, separately assessing the impact of different domains of fatigue on RTW with a validated questionnaire (EORTC QLQ-FA12). Using a more granular indicator, we showed that, when taking into account multiple physical and psychological symptoms, none of the subdomains of fatigue was correlated with RTW. Still, our results show a trend for a negative impact of emotional and physical fatigue on employment after BC.

Psychological factors were also associated with RTW. These factors may be induced by cancer diagnosis, cancer symptoms, or cancer treatments; they also may preexist or be increased by cancer. Consistent with the literature, we found that anxiety and/or depression were associated with RTW. The literature is fragmented and rarely includes physical and psychological symptoms simultaneously, whereas our analysis included multiple symptoms showing that several physical toxicities as well as several psychological symptoms were strongly and negatively correlated with RTW. Thus, our results suggest the multidimensional aspect of RTW and the importance of accounting for various health domains.

Our results are based on a large prospective study of patients recruited in 26 different centers across France. Our study presents several strengths, namely its large sample size, its longitudinal design, and the quality of the data collected. The data included detailed information on treatment and health status before diagnosis and at first post-treatment visit. The study included physical treatment-related toxicities, collected during a face-to-face examination and through validated quality-of-life questionnaires specific to BC, and also psychological symptoms, which often were not included in previous studies. The longitudinal design allowed us to collect those symptoms 1 year before our measure of RTW and thus to minimize bias occurring in cross-sectional design when simultaneously assessing the variable of interest and the outcome. Working conditions shown to be related to RTW, such as employer accommodation and support or attitudes about work since diagnosis, were not assessed. Yet, occupational category or part-time employment were taken.
into consideration. As in any longitudinal study, our data suffer from attrition, with approximately 18% of patients lost to follow-up. This could have affected the rate of non-RTW (21%), yet it was close to the rate found in a French national population-based survey (25%). As usually observed in the literature, patients with a higher socioeconomic position were more likely to respond. The final sample was still large and allowed us to model the influence of different therapeutic strategies and of multiple physical and psychological symptoms on RTW. To our knowledge, this report is the first to include both physical and psychological symptoms and to control for prediagnosis comorbidities and socioeconomic status on such an important sample. Given the importance of employment for rehabilitation, it is essential to provide patients with BC with programs to support them in job reintegration. However, even though returning to the workplace allows many patients to maintain a sense of normalcy or control, a substantial proportion of them need to take time to recover, especially if they experience long-lasting psychological symptoms. Consistent with 2 systematic reviews investigating the effect of interventions on RTW among cancer survivors, our results highlight the need to propose multidisciplinary interventions that not only focus on vocational issues but also involve physical and psychosocial components, for helping patients with BC to reintegrate the workforce. In particular, this comprehensive study identified potentially vulnerable patients and thus warrants additional research focusing on these patients who lag behind and on supportive interventional strategies to facilitate their RTW.

REFERENCES
1. De Angelis R, Sant M, Coleman MP, et al: Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE--5 a population-based study. Lancet Oncol 15:23-34, 2014
2. GLOBOCAN (IARC): Population fact sheets, Europe, 2018 http://gco.iarc.fr/today/datafactsheets/populations/908-europe-fact-sheets.pdf
3. de Boer AGEM, Taskila T, Ojajärvi A, et al: Cancer survivors and unemployment: A meta-analysis and meta-regression. JAMA 301:753-762, 2009
4. Surveillance Epidemiology, and End Results Program (SEER): Cancer Stat Facts: Female Breast Cancer. https://seer.cancer.gov/statfacts/html/breast.html
5. Mehnert A, de Boer A, Feuerstein M: Employment challenges for cancer survivors. Cancer 119:2151-2159, 2013 (suppl 11)

AFFILIATIONS
1. Université de Paris, ECEVE UMR 1123, INSERM (National Institute for Health and Medical Research), Paris, France
2. Clinical Research Department, Gustave Roussy, Villejuif, France
3. Breast Cancer Unit, Department of Medical Oncology, Gustave Roussy, Villejuif, France
4. INSERM Unit U 981, Villejuif, France
5. Sorbonne Université, INSERM, Institut Pierre Louis d’Épidémiologie et de Santé Publique, Paris, France
6. Department of Supportive Care, Gustave Roussy, Université Paris-Saclay, Villejuif, France
7. Laboratoire de Psychopathologie et Processus de Santé (EA 4057), Université de Paris, Paris, France
8. Clinical Research Department, Centre Georges-François Leclerc, Dijon, France
9. INSERM U1018, Center for Research in Epidemiology and Population Health, Villejuif, France
10. Department of Medical Oncology, Institut Curie, Paris, France
11. Institut de Cancérologie de Lorraine Alexis Vautrin, Vandoeuvre les Nancy, France
12. Centre Léon Berard, Lyon, France
13. Centre Oscar Lambret, Lille, France
14. Centre Français Baclesse, Caen, France
15. UNICANCER, Paris, France

CORRESPONDING AUTHOR
Agnes Dumas, PhD, Gustave Roussy Institute, B2M, U1018, 114 rue Edouard-Vaillant, Villejuif, 94805, France; e-mail: agnes.dumas@gustaveroussy.fr.

PRIOR PRESENTATION
Presented at the ASCO Annual Meeting, Chicago, Illinois, May 31-June 4, 2019.

SUPPORT
Supported by French Foundation for Cancer Research Grant No. ARC, PQA1 RF20170205420, and by Susan G. Komen Career Catalyst Research Grant No. CCR17483507 to I.V.L. and the Philanthropic Odyssea Gustave Roussy Program. The CANTO study is supported by the French Government under the Investment for the Future program managed by the National Research Agency, Grant No. ANR-10-COH0-0004.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT
Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI https://doi.org/10.1200/JCO.19.01726.

AUTHOR CONTRIBUTIONS
Conception and design: Agnes Dumas, Ines Vaz Luis, Antonio Di Meglio, Sarah Dauchy, Patrick Anveux, Fabrice Andre, Gwenn Menvielle
Financial support: Ines Vaz Luis
Administrative support: Jerome Lemonnier
Provision of study material or patients: Suzette Delalage, Paul Cottu, Florence Lerebours, Anne Lesur, Christelle Levy, Laurence Vanlemmens
Collection and assembly of data: Agnes Dumas, Ines Vaz Luis, Sandrine Pinto, Sarah Dauchy, Suzette Delalage, Patrick Anveux, Charles Coutant, Anne Lesur, Florence Lerebours, Olivier Tredan, Laurence Vanlemmens, Christelle Levy, Jerome Lemonnier, Christelle Mesleard, Fabrice Andre, Gwenn Menvielle
Data analysis and interpretation: Agnes Dumas, Ines Vaz Luis, Thomas Bovagnet, Maysam El Mouhebb, Antonio Di Meglio, Sandrine Pinto, Cecile Charles, Suzette Delalage, Charles Coutant, Paul Cottu, Anne Lesur, Laurence Vanlemmens, Fabrice Andre, Gwenn Menvielle
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
6. Tiedtke C, de Rijk A, Dierckx de Casterlé B, et al: Experiences and concerns about ‘returning to work’ for women breast cancer survivors: A literature review. Psychooncology 19:677-683, 2010
7. Feuerstein M, Todd BL, Moskwitz MC, et al: Work in cancer survivors: A model for practice and research. J Cancer Surviv 4:415-437, 2010
8. Wang L, Hong BY, Kennedy SA, et al: Predictors of unemployment after breast cancer surgery: A systematic review and meta-analysis of observational studies. J Clin Oncol 36:1888-1879, 2018
9. Aflı A, Baffert S, Soilli AL, et al: Determinants of return at work of breast cancer patients: Results from the OPTISONSO1 French prospective study. BMJ Open 8: e020276, 2018
10. Jagsi R, Abrahamse PH, Lee KL, et al: Treatment decisions and employment of breast cancer patients: Results of a population-based survey. Cancer 123: 4791-4799, 2017
11. Lundh MH, Lamping C, Nordin K, et al: Sickness absence and disability pension following breast cancer–A population-based matched cohort study. Breast 23: 844-851, 2014
12. Paalman CH, van Leeuwen FE, Aaronson NK, et al: Employment and social benefits up to 10 years after breast cancer diagnosis: A population-based study. Br J Cancer 114:81-87, 2016
13. Ahn E, Cho J, Shin DW, et al: Impact of breast cancer diagnosis and treatment on work-related life and factors affecting them. Breast Cancer Res Treat 116: 609-616, 2009
14. Blinder VS, Patil S, Third A, et al: Return to work in low-income Latina and non-Latina white breast cancer survivors: A 3-year longitudinal study. Cancer 118: 1664-1674, 2012
15. Hayes SC, Johansson K, Stout NL, et al: Upper-body morbidity after breast cancer: Incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer 118:2237-2249, 2012 (suppl 8)
16. Bower JE, Ganz PA, Desmond KA, et al: Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743-753, 2000
17. Hartung TJ, Brähler E, Faller H, et al: The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. Eur J Cancer 72:46-53, 2017
18. Jim HS, Phillips KM, Chait S, et al: Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578-3587, 2012
19. Bijker R, Duits SFA, Smith SN, et al: Functional impairments and work-related outcomes in breast cancer survivors: A systematic review. J Occup Rehabil 28: 429-451, 2018
20. Carlsen K, Jensen AJ, Rugulies R, et al: Self-reported work ability in long-term breast cancer survivors. A population-based questionnaire study in Denmark. Acta Oncol 52:423-429, 2013
21. Lindbohm ML, Kuosma E, Taskiila T, et al: Early retirement and non-employment after breast cancer. Psychooncology 23:634-641, 2014
22. Tikk C, Verbeek JH, Tammenga SJ, et al: Rehabilitation and return to work after cancer. Literature review. Barcelona, European Agency for Safety and Health at Work (EU-OSHA), 2017
23. Kvillermo P, Mittendorfer-Rutz E, Bränström R, et al: Sickness absence and disability pension after breast cancer diagnosis: A 5-year nationwide cohort study. J Clin Oncol 35:2044-2052, 2017
24. Cardoso F, Kyriakides S, Ohno S, et al: Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 10.1093/annonc/mdz173 (epub ahead of print on June 4, 2019)
25. Goetz MP, Gradishar WJ, Anderson BO, et al: NCCN guidelines insights: Breast cancer, version 3.2018. J Natl Compr Canc Netw 17:118-126, 2019
26. INCa (French Cancer Institute): La vie deux ans après un diagnostic de cancer – De l’annonce à l’après-cancer, Études et enquêtes. Boulogne-Billancourt, INCa 2014
27. Richard J, Andler R, Guignard R: Baromètre santé 2017. Méthode d’enquête. Objectifs, contexte de mise en place et protocole. Saint-Maurice, Santé Publique France, 2018
28. Vaz-Luis I, Cottu P, Mesleard C, et al: UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open 4:e000562, 2019
29. Institut National de la Statistique et des Etudes Économiques: Professions et catégories socioprofessionnelles: PCS 2003. Montrouge, INSEE, 2019
30. American Joint Committee on Cancer: Breast Cancer Staging: https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf
31. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
32. US Department of Health and Human Services: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14QuickReference_5r7.pdf
33. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
34. Sprangers MA, Groenvold M, Arraras JI, et al: The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J Clin Oncol 14:2756-2768, 1996
35. Brähler E, Gielissen MF, Schmitt IC, et al: Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: A meta-analysis involving 12,327 breast cancer survivors. Ann Oncol 27:965-974, 2016
36. Goetz MP, Gradishar WJ, Anderson BO, et al: NCCN guidelines insights: Breast cancer, version 3.2018. J Natl Compr Canc Netw 17:118-126, 2019
37. Thorsen AH, Tomaszewski KA, Hammerlid E, et al: International psychometric validation of an EORTC quality-of-life module measuring cancer related fatigue (EORTC QLQ-FA12). J Natl Cancer Inst 109:djw273, 2017
38. Zigmund AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370, 1983
39. Orgaard S, Hald JN, Dierschke C, et al: Economic Co-operation and Development: Labour force participation rate, by sex and age group OECD (Organisation for economic co-operation and development). 2019 https://stats.oecd.org/
40. Balak F, Roelen CAM, Koopmans PC, et al: Return to work after early-stage breast cancer: A cohort study into the effects of treatment and cancer-related symptoms. J Occup Rehabil 18:267-272, 2008
41. Ekenga CC, Pérez M, Margenthaler JA, et al: Early-stage breast cancer and employment participation after 2 years of follow-up: A comparison with age-matched controls. Cancer 124:2026-2035, 2018
42. Lee MK, Kang HS, Lee KS, et al: Three-year prospective cohort study of factors associated with return to work after breast cancer diagnosis. J Occup Rehabil 27: 547-558, 2017

© 2019 by American Society of Clinical Oncology
43. Peugniez C, Fantoni S, Leroyer A, et al: Return to work after treatment for breast cancer: Single-center experience in a cohort of 273 patients. Ann Oncol 21:2124-2125, 2010
44. Pivot X, Gilgrov J, Müller V, et al: Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): An open-label randomised study. Lancet Oncol 14:962-970, 2013
45. Johnson A, Fornander T, Olsson M, et al: Factors associated with return to work after breast cancer treatment. Acta Oncol 46:90-96, 2007
46. Maunsell E, Drolet M, Brisson J, et al: Work situation after breast cancer: Results from a population-based study. J Natl Cancer Inst 96:1813-1822, 2004
47. Noeres D, Park-Simon T-W, Grabow J, et al: Return to work after treatment for primary breast cancer over a 6-year period: Results from a prospective study comparing patients with the general population. Support Care Cancer 21:1901-1909, 2013
48. Bouknight RR, Bradley CJ, Luo Z: Correlates of return to work for breast cancer survivors. J Clin Oncol 24:345-353, 2006
49. Fantoni SQ, Peugniez C, Duhamel A, et al: Factors related to return to work by women with breast cancer in northern France. J Occup Rehabil 20:49-58, 2010
50. Nilsson M, Petersson L-M, Wennman-Larsen A, et al: Adjustment and social support at work early after breast cancer surgery and its associations with sickness absence. Psychooncology 22:2765-2762, 2013
51. Tamminga SJ, Coenen P, Paalman C, et al: Factors associated with an adverse work outcome in breast cancer survivors 5-10 years after diagnosis: A cross-sectional study. J Cancer Surviv 13:108-116, 2019
52. Peteet JR: Cancer and the meaning of work. Gen Hosp Psychiatry 22:200-205, 2000
53. de Boer AG, Taskila T, Tamminga SJ, et al: Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev (2):CD007569, 2011
54. Hunter EG, Gibson RW, Arbesman M, et al: Systematic review of occupational therapy and adult cancer rehabilitation: Part 2. Impact of multidisciplinary rehabilitation and psychosocial, sexuality, and return-to-work interventions. Am J Occup Ther 71:7102100040p1-7102100040p8, 2017
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO)

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rcw or ascopubs.org/journal/jco/site/ifc.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Ines Vaz Luis
Honoraria: Novartis, Kephren, AstraZeneca
Consulting or Advisory Role: Ipsen

Sarah Dauchy
Honoraria: MSD Oncology, Pierre Fabre, SERVIER, Novartis, MSD Oncology
Travel, Accommodations, Expenses: SERVIER

Suzette Delaloge
Consulting or Advisory Role: AstraZeneca
Research Funding: AstraZeneca (Inst), Pfizer (Inst), Genentech (Inst), Puma (Inst), Eli Lilly (Inst), Novartis (Inst), Sanofi (Inst)
Travel, Accommodations, Expenses: Pfizer, AstraZeneca, Roche

Paul Cottu
Honoraria: Pfizer, Novartis, Roche, AstraZeneca, NanoString Technologies
Consulting or Advisory Role: Pfizer, Novartis, Genentech, Context Therapeutics
Research Funding: Novartis (Inst), Pfizer (Inst)
Travel, Accommodations, Expenses: Roche, Novartis, Pfizer, Eli Lilly

Olivier Tredan
Consulting or Advisory Role: Roche, Pfizer, Novartis, Eli Lilly, AstraZeneca, MSD Oncology
Research Funding: Roche, Novartis, Pfizer, Eli Lilly, Bristol-Myers Squibb, MSD Oncology, AstraZeneca
Travel, Accommodations, Expenses: Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca

Fabrice Andre
Research Funding: AstraZeneca (Inst), Novartis (Inst), Pfizer (Inst), Eli Lilly (Inst), Roche (Inst), Daiichi (Inst)
Travel, Accommodations, Expenses: Novartis, Roche, GlaxoSmithKline, AstraZeneca

No other potential conflicts of interest were reported.
### Table A1. Characteristics of Respondents and Nonrespondents (N = 2,284)

| Characteristic                                     | Respondents (n = 1,874) | Lost to Clinical Follow-Up at T2 (n = 124) | No Information on RTW at T2 (n = 286) | P  |
|---------------------------------------------------|-------------------------|------------------------------------------|--------------------------------------|----|
| Age, years                                        |                         |                                          |                                      |    |
| 18-39                                             | 248 (13.2)              | 9 (7.3)                                  | 45 (15.7)                            | .04|
| 40-49                                             | 866 (46.2)              | 54 (43.5)                                | 142 (49.7)                           |    |
| 50-56                                             | 760 (40.6)              | 61 (49.2)                                | 99 (34.6)                            |    |
| Occupational class                                |                         |                                          |                                      | .01|
| Self-employed (farmers, craftsmen, and shopkeepers)| 99 (5.4)                | 9 (7.7)                                  | 22 (7.9)                             |    |
| Clerks                                            | 713 (39.1)              | 56 (47.9)                                | 136 (49.1)                           |    |
| Manual workers                                    | 122 (6.7)               | 9 (7.7)                                  | 15 (5.4)                             |    |
| Technicians and associate professionals           | 441 (24.2)              | 20 (17.1)                                | 49 (17.7)                            |    |
| Professionals and managers                        | 449 (24.6)              | 23 (19.7)                                | 55 (19.9)                            |    |
| Missing                                           | 50 (---)                | ---                                      | ---                                  |    |
| Stage                                             |                         |                                          |                                      | .39|
| Stage I                                           | 839 (44.8)              | 52 (43.7)                                | 131 (45.8)                           |    |
| Stage II                                          | 824 (44.0)              | 54 (45.4)                                | 134 (46.9)                           |    |
| Stage III                                         | 211 (11.3)              | 13 (10.9)                                | 21 (7.3)                             |    |
| Charlson comorbidity index                        |                         |                                          |                                      | .59|
| 0                                                 | 1,506 (86.0)            | 96 (85.7)                                | 232 (87.5)                           |    |
| 1                                                 | 128 (7.3)               | 11 (9.8)                                 | 15 (5.7)                             |    |
| ≥ 2                                               | 117 (6.7)               | 5 (4.5)                                  | 18 (6.8)                             |    |
| Missing                                           | 123 (---)               | ---                                      | ---                                  |    |
| Radiotherapy                                      |                         |                                          |                                      | .25|
| Yes                                               | 1,716 (91.6)            | 104 (87.4)                               | 264 (92.3)                           |    |
| No                                                | 158 (8.4)               | 15 (12.6)                                | 22 (7.7)                             |    |
| Stage                                             |                         |                                          |                                      | .39|
| Stage I                                           | 839 (44.8)              | 52 (43.7)                                | 131 (45.8)                           |    |
| Stage II                                          | 824 (44.0)              | 54 (45.4)                                | 134 (46.9)                           |    |
| Stage III                                         | 211 (11.3)              | 13 (10.9)                                | 21 (7.3)                             |    |
| Surgery                                           |                         |                                          |                                      | .71|
| Conservative                                      | 1,310 (69.9)            | 83 (68.6)                                | 206 (72.0)                           |    |
| Mastectomy                                        | 564 (30.1)              | 38 (31.4)                                | 80 (28.0)                            |    |
| Lymph node surgery                                |                         |                                          |                                      | .22|
| Sentinel node dissection                          | 1,011 (53.9)            | 67 (55.4)                                | 170 (59.4)                           |    |
| Axillary dissection                               | 863 (46.1)              | 54 (44.6)                                | 116 (40.6)                           |    |
| Radiotherapy                                      |                         |                                          |                                      | .25|
| Yes                                               | 1,716 (91.6)            | 104 (87.4)                               | 264 (92.3)                           |    |
| No                                                | 158 (8.4)               | 15 (12.6)                                | 22 (7.7)                             |    |
| Chemotherapy                                      |                         |                                          |                                      | .14|
| Yes                                               | 1,230 (65.6)            | 68 (57.1)                                | 181 (63.3)                           |    |
| No                                                | 644 (34.4)              | 51 (42.9)                                | 105 (36.7)                           |    |

(continued on following page)
**TABLE A1.** Characteristics of Respondents and Nonrespondents (N = 2,284) (continued)

| Characteristic | Respondents (n = 1,874) | Lost to Clinical Follow-Up at T2 (n = 124) | No Information on RTW at T2 (n = 286) | P |
|---------------|-------------------------|------------------------------------------|--------------------------------------|---|
| Hormone therapy | No. | %  | No. | %  | No. | %  | | .02 |
| Yes | 1,546 | 82.5 | 95 | 81.2 | 216 | 75.5 | | |
| No | 328 | 17.5 | 22 | 18.8 | 70 | 24.5 | | |
| Trastuzumab | | | | | | | .82 |
| Yes | 283 | 15.1 | 16 | 13.7 | 40 | 14.0 | | |
| No | 1,591 | 84.9 | 101 | 86.3 | 246 | 86.0 | | |

NOTE. France, CANTO cohort, 2018; not imputed data set.

Abbreviations: RTW, return to work; T2, post-treatment visit 2 (2 years after diagnosis).
| Factor                                      | Total | %  | No RTW | %  | P  |
|--------------------------------------------|-------|----|--------|----|----|
| **Socioeconomic covariates at diagnosis**  |       |    |        |    |    |
| Age, years                                 |       |    |        |    |    |
| 18-39                                      | 248   | 13.2| 52     | 21.0| b  |
| 40-49                                      | 866   | 46.2| 160    | 18.5|
| 50-56                                      | 760   | 40.6| 187    | 24.6|
| Missing                                    | 0     | —  | 0      | —  |    |
| Having a partner                           |       |    |        |    |    |
| No                                         | 292   | 15.6| 64     | 21.9| .88|
| Yes                                        | 1,566 | 83.6| 334    | 21.3|
| Missing                                    | 16    | —  | 1      | —  |    |
| No. of children                            |       |    |        |    |    |
| 0                                          | 489   | 28.1| 118    | 24.1| .16|
| 1                                          | 461   | 26.5| 99     | 21.5|
| > 1                                        | 790   | 45.4| 155    | 19.6|
| Missing                                    | 134   | —  | 27     | —  |    |
| Occupational class                         |       |    |        |    |    |
| Professionals and managers                 | 457   | 24.4| 65     | 14.2| c  |
| Technicians and associate professionals    | 445   | 23.7| 76     | 17.1|
| Clerks, service and sales workers          | 730   | 39.0| 187    | 25.6|
| Farmers, craftsmen, and shopkeepers        | 99    | 5.3 | 19     | 19.2|
| Manual workers                             | 125   | 6.7 | 47     | 37.6|
| Missing                                    | 18    | —  | 5      | —  |    |
| Income of the household                    |       |    |        |    |    |
| > 4,000€ per month                         | 322   | 18.1| 95     | 29.5| c  |
| 2,000-4,000€ per month                     | 865   | 48.7| 191    | 22.1|
| < 2,000€ per month                         | 590   | 33.2| 88     | 14.9|
| Missing                                    | 97    | —  | 25     | —  |    |
| Working hours                              |       |    |        |    |    |
| Full-time employment                       | 1,301 | 75.6| 241    | 18.5| c  |
| Part-time employment                       | 421   | 24.4| 111    | 26.4|
| Missing                                    | 152   | —  | 47     | —  |    |
| Work-life imbalance                        |       |    |        |    |    |
| Equal importance to personal and professional life | 888   | 48.8| 724    | 50.5| .79|
| Personal life is more important            | 746   | 41.0| 564    | 39.4|
| Professional life is more important        | 185   | 10.2| 145    | 10.1|
| Missing                                    | 55    | —  | 42     | —  |    |

(continued on following page)
| Factor                                      | Total |     |        |        |        |
|---------------------------------------------|-------|-----|--------|--------|--------|
|                                             | No.   | %   | No.    | %      | P      |
| Charlson comorbidity indexa                 |       |     |        |        |        |
| 0                                           | 1,506 | 86.0| 299    | 19.9   |        |
| ≥ 1                                          | 245   | 14.0| 72     | 29.4   |        |
| Missing                                     | 123   | —   | 28     | —      |        |
| Additional comorbid conditionsa             |       |     |        |        |        |
| < 3                                         | 1,472 | 78.5| 287    | 19.5   |        |
| ≥ 3                                         | 382   | 20.4| 108    | 28.3   |        |
| Missing                                     | 20    | —   | 4      | —      |        |
| Treatment                                   |       |     |        |        |        |
| Radiotherapy                                |       |     |        |        |        |
| No                                          | 158   | 8.4 | 39     | 24.7   | .32   |
| Yes                                         | 1,716 | 91.6| 360    | 21.0   |       |
| Missing                                     | 0     | —   | 0      | —      |       |
| Types of surgery and node dissection        |       |     |        |        |        |
| Conservative surgery + sentinel node dissection | 893 | 47.7| 147    | 16.5   |        |
| Conservative surgery + axillary dissection  | 417   | 22.3| 92     | 22.1   |       |
| Mastectomy + sentinel node dissection       | 118   | 6.3 | 25     | 21.2   |       |
| Mastectomy + axillary dissection            | 446   | 23.8| 135    | 30.3   |       |
| Missing                                     | 0     | —   | 0      | —      |       |
| Systemic treatment                          |       |     |        |        |        |
| Chemotherapy + hormone therapy              | 772   | 41.2| 163    | 21.1   |        |
| None                                        | 65    | 3.5 | 13     | 20.0   |       |
| Hormone therapy alone                       | 579   | 30.9| 92     | 15.9   |       |
| Chemotherapy alone                          | 175   | 9.3 | 45     | 25.7   |       |
| Chemotherapy + trastuzumab                  | 88    | 4.7 | 30     | 34.1   |       |
| Chemotherapy + trastuzumab + hormone therapy| 195   | 10.4| 56     | 28.7   |       |
| Missing                                     | 0     | —   | 0      | —      |       |
| Toxicities and PROs*                        |       |     |        |        |        |
| No. of severe toxicities*                   |       |     |        |        |        |
| 0                                           | 1,562 | 83.4| 300    | 19.2   |        |
| ≥ 1                                         | 287   | 15.3| 93     | 32.4   |       |
| Missing                                     | 25    | —   | 6      | —      |       |
| Breast morbidity                            |       |     |        |        |        |
| No                                          | 1,339 | 71.5| 247    | 18.4   |        |
| Yes                                         | 431   | 23.0| 129    | 29.9   |       |
| Missing                                     | 104   | —   | 23     | —      |       |
| Arm morbidity                               |       |     |        |        |        |
| No                                          | 1,298 | 69.3| 214    | 16.5   |        |
| Yes                                         | 475   | 25.3| 163    | 34.3   |       |
| Missing                                     | 101   | —   | 22     | —      |       |

(continued on following page)
## TABLE A2. Factors Associated with Non-RTW at the Second Post-Treatment Visit, 2 Years After Diagnosis: Univariate Analysis (n = 1,874) (continued)

| Factor                        | Total |       | No RTW |       | P   |
|-------------------------------|-------|-------|--------|-------|-----|
|                               | No    | %     | No     | %     |     |
| Systemic therapy adverse effects |       |       |        |       |     |
| No                            | 1,615 | 86.2  | 308    | 19.1  |     |
| Yes                           | 158   | 8.4   | 68     | 43.0  |     |
| Missing                       | 101   | —     | 23     | —     |     |
| Severe physical fatigue       |       |       |        |       |     |
| No                            | 1,373 | 73.3  | 231    | 16.8  |     |
| Yes                           | 399   | 21.3  | 146    | 36.6  |     |
| Missing                       | 102   | —     | 22     | —     |     |
| Severe cognitive fatigue      |       |       |        |       |     |
| No                            | 1,496 | 79.8  | 277    | 18.5  |     |
| Yes                           | 275   | 14.7  | 100    | 36.4  |     |
| Missing                       | 103   | —     | 22     | —     |     |
| Severe emotional fatigue      |       |       |        |       |     |
| No                            | 1,459 | 77.9  | 252    | 17.3  |     |
| Yes                           | 309   | 16.5  | 123    | 39.8  |     |
| Missing                       | 106   | —     | 24     | —     |     |
| Anxiety                       |       |       |        |       |     |
| None                          | 951   | 50.7  | 136    | 14.3  | c   |
| Possible case                 | 467   | 24.9  | 127    | 27.2  |     |
| Probable case                 | 360   | 19.2  | 115    | 31.9  |     |
| Missing                       | 96    | —     | 21     | —     |     |
| Depression                    |       |       |        |       |     |
| None                          | 1,484 | 79.2  | 266    | 17.9  | c   |
| Possible case                 | 196   | 10.5  | 59     | 30.1  |     |
| Probable case                 | 98    | 5.2   | 53     | 54.1  |     |
| Missing                       | 96    | —     | 21     | —     |     |

NOTE. France, CANTO cohort, 2018; not imputed data set.
Abbreviations: CTCAE, Common Toxicity Criteria Adverse Events; PRO, patient-reported outcome; RTW, return to work.

*Variables collected at diagnosis.

*Variables collected at the first post-treatment visit (3-6 months after end of primary treatment).

*CTCAE grade 3 cardiovascular, gynecologic, rheumatological, GI, dermatological, pulmonary, or neurologic toxicity.
### TABLE A3. Factors Associated with Non-RTW at the Second Post-Treatment Visit, 2 Years After Diagnosis: Multivariable Logistic Regressions

| Factors                          | %   | OR   | 95% CI       | OR   | 95% CI       |
|---------------------------------|-----|------|--------------|------|--------------|
| **Socioeconomic covariates at diagnosis** |     |      |              |      |              |
| Age, years                      |     |      |              |      |              |
| 18-39                           | 13.2| 1.00 |              | 1.00 |              |
| 40-49                           | 46.2| 1.03 | 0.70 to 1.50 | 1.00 | 0.67 to 1.49 |
| 50-56                           | 40.6| 1.59 | 1.07 to 2.36 | 1.60 | 1.05 to 2.43 |
| Having a partner                |     |      |              |      |              |
| No                              | 15.9| 1.00 |              | 1.00 |              |
| Yes                             | 84.1| 1.15 | 0.80 to 1.67 | 1.17 | 0.79 to 1.74 |
| No. of children                 |     |      |              |      |              |
| 0                               | 28.9| 1.00 |              | 1.00 |              |
| 1                               | 26.6| 0.94 | 0.68 to 1.31 | 0.88 | 0.63 to 1.24 |
| > 1                             | 44.5| 0.91 | 0.66 to 1.24 | 0.88 | 0.63 to 1.22 |
| Occupational class              |     |      |              |      |              |
| Professionals and managers      | 24.6| 1.00 |              | 1.00 |              |
| Technicians and associate       | 24.0| 1.00 | 0.68 to 1.47 | 0.95 | 0.64 to 1.42 |
| associate professionals         | 39.4| 1.48 | 1.04 to 2.13 | 1.41 | 0.97 to 2.06 |
| Clerks                          | 5.3 | 1.14 | 0.62 to 2.07 | 1.08 | 0.57 to 2.04 |
| Self-employed (farmers, craftsmen, and shopkeepers) | 6.7 | 2.34 | 1.42 to 3.88 | 2.17 | 1.28 to 3.68 |
| Manual workers                  |     |      |              |      |              |
| Income of the household         |     |      |              |      |              |
| > 4,000€ per month              | 32.9| 1.00 |              | 1.00 |              |
| 2,000-4,000€ per month          | 48.7| 1.36 | 0.99 to 1.86 | 1.26 | 0.91 to 1.75 |
| < 2,000€ per month              | 18.4| 1.94 | 1.27 to 2.96 | 1.65 | 1.06 to 2.59 |
| Working hours                   |     |      |              |      |              |
| Full-time employment            | 75.3| 1.00 |              | 1.00 |              |
| Part-time employment            | 24.7| 1.50 | 1.12 to 1.99 | 1.51 | 1.12 to 2.04 |
| Work-life imbalance             |     |      |              |      |              |
| Equal importance to personal and professional life | 47.4| 1.00 |              | 1.00 |              |
| Personal life is more important | 39.8| 1.28 | 0.99 to 1.65 | 1.29 | 0.99 to 1.69 |
| Professional life is more important | 9.9 | 1.14 | 0.75 to 1.74 | 1.07 | 0.68 to 1.66 |
| Clinical covariates             |     |      |              |      |              |
| Stage                           |     |      |              |      |              |
| Stage I                         | 44.8| 1.00 |              | 1.00 |              |
| Stage II                        | 44.0| 1.29 | 0.94 to 1.77 | 1.41 | 1.01 to 1.97 |
| Stage III                       | 11.3| 1.87 | 1.18 to 2.97 | 2.00 | 1.23 to 3.25 |
| Charlson comorbidity index*     |     |      |              |      |              |
| 0                               | 85.9| 1.00 |              | 1.00 |              |
| ≥ 1                             | 14.1| 1.55 | 1.12 to 2.14 | 1.52 | 1.08 to 2.14 |
| Additional comorbid conditions*  |     |      |              |      |              |
| < 3                             | 79.4| 1.00 |              | 1.00 |              |
| ≥ 3                             | 20.6| 1.62 | 1.23 to 2.14 | 1.38 | 1.02 to 1.86 |

(continued on following page)
TABLE A3. Factors Associated with Non-RTW at the Second Post-Treatment Visit, 2 Years After Diagnosis: Multivariable Logistic Regressions (continued)

| Factors                                      | %  | OR    | 95% CI       | OR    | 95% CI       |
|----------------------------------------------|----|-------|--------------|-------|--------------|
| **Treatment**                                |    |       |              |       |              |
| Radiotherapy                                 |    |       |              |       |              |
| No                                           | 8.4| 1.00  |              | 1.00  |              |
| Yes                                          | 91.6| 0.79  | 0.49 to 1.26 | 0.77  | 0.47 to 1.26 |
| **Combinations of local treatments**         |    |       |              |       |              |
| Conservative surgery + sentinel node dissection | 47.7| 1.00  |              | 1.00  |              |
| Conservative surgery + axillary dissection   | 22.2| 1.13  | 0.78 to 1.62 | 1.05  | 0.72 to 1.55 |
| Mastectomy + sentinel node dissection        | 6.3 | 1.14  | 0.64 to 2.03 | 1.15  | 0.63 to 2.11 |
| Mastectomy + axillary dissection             | 23.8| 1.70  | 1.18 to 2.46 | 1.64  | 1.11 to 2.41 |
| **Trastuzumab**                              |    |       |              |       |              |
| No                                           | 84.9| 1.00  |              | 1.00  |              |
| Yes                                          | 15.1| 1.56  | 1.13 to 2.14 | 1.53  | 1.10 to 2.15 |
| **Hormone therapy**                          |    |       |              |       |              |
| No                                           | 17.5| 1.00  |              | 1.00  |              |
| Yes                                          | 82.5| 0.69  | 0.51 to 0.93 | 0.72  | 0.52 to 0.99 |
| **Type of chemotherapy**                     |    |       |              |       |              |
| No chemotherapy                              | 34.4| 1.00  |              | 1.00  |              |
| Anthracycline-taxane based                    | 61.3| 1.06  | 0.76 to 1.49 | 0.98  | 0.69 to 1.41 |
| Other type of regimen                        | 4.3 | 1.19  | 0.65 to 2.16 | 1.05  | 0.56 to 1.96 |
| **Toxicities and PROsb**                     |    |       |              |       |              |
| $\geq 1$ CTCAE severe physical toxicityc     |    |       |              |       |              |
| No                                           | 84.5| —     |              | 1.00  |              |
| At least one                                 | 15.5| —     |              | 1.59  | 1.16 to 2.18 |
| **Severe breast morbidity**                  |    |       |              |       |              |
| No                                           | 75.3| —     |              | 1.00  |              |
| Yes                                          | 24.7| —     |              | 0.97  | 0.70 to 1.33 |
| **Severe arm morbidity**                     |    |       |              |       |              |
| No                                           | 73.0| —     |              | 1.00  |              |
| Yes                                          | 27.0| —     |              | 1.59  | 1.19 to 2.13 |
| **Severe systemic therapy adverse effects**  |    |       |              |       |              |
| No                                           | 90.9| —     |              | 1.00  |              |
| Yes                                          | 9.1 | —     |              | 1.43  | 0.96 to 2.15 |
| **Severe physical fatigue**                  |    |       |              |       |              |
| No                                           | 77.2| —     |              | 1.00  |              |
| Yes                                          | 22.8| —     |              | 1.31  | 0.94 to 1.83 |
| **Severe cognitive fatigue**                 |    |       |              |       |              |
| No                                           | 84.3| —     |              | 1.00  |              |
| Yes                                          | 15.7| —     |              | 1.03  | 0.71 to 1.49 |
| **Severe emotional fatigue**                 |    |       |              |       |              |
| No                                           | 82.2| —     |              | 1.00  |              |
| Yes                                          | 17.8| —     |              | 1.45  | 0.99 to 2.13 |

(continued on following page)
| Factors         | %  | OR   | 95% CI       | OR   | 95% CI       |
|-----------------|----|------|--------------|------|--------------|
| Anxiety         |    |      |              |      |              |
| Noncase         | 53.3 |    | -            | 1.00 |              |
| Doubtful case   | 26.3 |    | -            | 1.71 | 1.26 to 2.31 |
| Case            | 20.4 |    | -            | 1.47 | 1.02 to 2.11 |
| Depression      |    |      |              |      |              |
| Noncase         | 83.4 |    | -            | 1.00 |              |
| Doubtful case   | 11.1 |    | -            | 1.05 | 0.70 to 1.58 |
| Case            | 5.5  |    | -            | 2.28 | 1.34 to 3.90 |

NOTE: France, CANTO cohort, 2018; imputed data set.
Abbreviations: CTCAE, Common Toxicity Criteria Adverse Events; PRO, patient-reported outcome; RTW, return to work.

*Variables collected at diagnosis.
**Variables collected at treatment the first post-treatment visit (3-6 months after end of primary treatment).
*CTCAE grade ≥ 3 cardiovascular, gynecologic, rheumatological, GI, dermatological, pulmonary, or neurologic toxicity.